Corxel Pharmaceuticals closed a $287 million financing to support global development of its oral GLP‑1 candidate, a program the company licensed from Vincentage. The round funds pivotal phase 2/3 studies aimed at establishing the pill’s efficacy versus injectable GLP‑1s and expands Corxel’s commercial runway as it pursues an obesity market opportunity. Investors backing the round signaled continued appetite for oral incretin assets despite crowded obesity markets.